SGMT
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ: SGMT · HEALTHCARE · BIOTECHNOLOGY
$7.71
+0.92% today
Updated 2026-05-08
Market cap
$476.11M
P/E ratio
—
P/S ratio
52.50x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$3 – $11
Volume
1.6M
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | $11.16M | $68.96M | $59.03M | $33.03M | $96.72M | $160.26M |
| Cash & equivalents | $10.21M | $68.70M | $56.73M | $158000.00 | $75.14M | $75.84M |
| Current assets | $10.81M | $68.74M | $58.66M | $32.79M | $96.65M | $152.77M |
| Total liabilities | $136.47M | $204.87M | $217.29M | $219.98M | $5.65M | $4.45M |
| Current liabilities | $2.08M | $1.91M | $2.44M | $5.28M | $5.65M | $4.45M |
| Long-term debt | — | — | — | — | — | — |
| Shareholder equity | $-125.31M | $-135.91M | $-158.26M | $-186.95M | $91.06M | $155.81M |
| Retained earnings | $-155.56M | $-166.93M | $-191.37M | $-221.87M | $-249.74M | $-295.31M |
| Accounts receivable | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — |